Targeted interventions for difficult-to-treat asthma.
Chronic persistent asthma has a significant burden in terms of healthcare-related expenses, decreased productivity and reduced quality of life for patients. Currently available guideline-directed therapy can control the majority of patients, but roughly one-third of patients will require additional care. This article reviews the barriers that hinder the ability of practitioners and patients to gain and maintain control of asthma, including inaccurate assessment measures, variability in patient response, and poor adherence. Strategies aimed at controlling difficult-to-treat disease, such as the use of biomarkers to assess control, are discussed. Newer and developing therapies that cater to specific types of asthmatic patients and may lead to improved outcomes in those patients for whom standard care is insufficient are also looked at.
Chipps
Bradley E
BE
Capital Allergy & Respiratory Disease Center, Sacramento, CA 95819, USA. bchipps@capitalallergy.com
Harder
Julia M
JM
D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D006801:Humans
D018927:Anti-Asthmatic Agents